NEW YORK (GenomeWeb) – RayBiotech today announced a partnership with XCellCure to develop a cardiovascular disease diagnostic kit.
The firms will co-market and co-distribute the kits worldwide with a focus initially on the research market and the longer term goal of making the technology available to the clinical diagnostics and prognostics spaces.
"XCellCure and its team has defined some of the most comprehensive and accurate biomarkers for diagnosing cardiovascular disorders to date," RayBiotech President, Chief Operating Officer, and Co-founder Rani Huang said in a statement. "We believe that combining XCellCure's biomarkers with RayBiotech's antibody array technology now allows for the most sensitive and accurate way to diagnose cardiovascular disease and its related disorders."
Norcross, Ga.-based RayBiotech develops antibody and protein array technologies. XCellCure is based in St. Louis and provides multiplexed microarray kits for the diagnosis and prognosis of acute myocardial infarction.
Financial and other terms of the deal were not disclosed.